



[ScienceEducationPatient Care & Advocacy](#)  
[Our Society](#)[Our Mission, Vision & Values](#)[Equality, Diversity & Inclusion](#)[EBMT](#)  
[Membership 2022](#)[Organisational Structure 2022](#)[Financial Highlights 2022](#)[EBMT](#)  
[Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print



Annalisa Ruggeri  
CTIWP Chair (ELECTED MARCH 2022, PREVIOUS CHAIR: Christian Chabannon)  
Italy

## Major achievements

The CTIWP activities are evolving quickly with the new treatments and different scenarios in the HCT, cell and gene therapy fields.

The CTIWP has been working to expand and moderate the CAR T community through partnerships with other organisations such as the [GoCART coalition](#) and [T2Evolve](#). The CTIWP has also worked with national registries like [OncodePACT](#) to secure funding for connecting these registries to national databases and increase the impact of the EBMT-based CAR T registry. In addition, the CTIWP has collaborated with the regulatory affairs community of EBMT to provide input on European legislation related to stem cell transplantation and cellular therapies, and to facilitate academic development and improve access to approved drugs. The CTIWP has also helped to harmonize the accreditation process for centers that perform CAR T therapies in collaboration with JACIE and GoCART, to avoid duplication of efforts ( [Reduced CART site qualification workload for JACIE accredited centres | EBMT](#)).

Understanding the biological mechanisms that may influence the HCT outcomes are among the main objectives of the CTIWP. The role of new tools for evaluating the impact of HLA in the setting of allogeneic transplantation in unrelated and also mismatched related donors transplant with the use of PTCY is currently under investigation. Different studies are ongoing exploring the role of HLA evolutionary divergence, and the role of the quantification of HLA-DP mismatch permissiveness. Also focusing on the role of microbiota for GVHD treatment or decontamination in case of multidrug resistant carriage is a topic of interest, such as the management of complications related to the cell therapy treatments

## Principal research studies

[Graft Engineering for allogeneic hematopoietic stem cell transplantation \(HSCT\) and modified donor lymphocyte infusion \(DLI\)](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

-

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

-

[Principal investigator](#)

[Moniek de Witte](#)

[Association between HLA evolutionary divergence and leukemia relapse after allogeneic SCT from 10/10 HLA matched related/unrelated donor](#)

Study type

Retrospective Studies

Diseases

Acute Myeloid Leukaemia (AML)

Acute Lymphatic Leukaemia (ALL)

Myelodysplastic (MDS) or MDS/MPN

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Allogeneic

Principal investigator

Pietro Crivello, Pietro Merli

## **Key publications**

2022

Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY:

A study on behalf of the EBMT cellular therapy & immunobiology working party

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

1st listed author

Nicole Santoro

Journal

Bone Marrow Transplant.

2022

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

1st listed author

Annalisa Ruggeri

Journal

Haematologica.

2022

Mother donors improve outcomes after HLA haploidentical transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the EBMT

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

[1st listed author](#)

[Loredana Ruggeri](#)

[Journal](#)

[Transplant Cell Ther.](#)

[2022](#)

[The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Nursing Research Committee](#)

[Nursing Scientific Committee](#)

[1st listed author](#)

[Rose Ellard](#)

[Journal](#)

[Clin Hematol Int.](#)

[2022](#)

[Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Lymphoma Working Party \(LWP\)](#)

[Patient Advocacy Committee](#)

[Trainee Committee](#)

[Nursing Research Committee](#)

[Nursing Scientific Committee](#)


[1st listed author](#)

[Nico Gagelmann](#)

[Journal](#)

[Lancet Haematol.](#)

[See the full list of the CTIWP 2022 publications](#)



**2019 2020 2021 2022**


<b>Oral presentations</b>	<b>16</b>	<b>8</b>	<b>4</b>	<b>2</b>
<b>Poster presentations</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>4</b>
<b>Educational events</b>	<b>6</b>	<b>4</b>	<b>5</b>	<b>7</b>

## Major educational events



[Event](#)

## **Virtual 48th Annual Meeting of the EBMT**



[Event](#)

## **EBMT-EHA 4th European CAR T-cell Meeting**



### **Event**

## **2nd Cellular Therapy & Immunobiology Working Party Workshop**

**Jan 14, 2022 - Jan 14, 2022 / Virtual Meeting**

**Discover more**

- 48th Annual Meeting of the EBMT: Cell Therapy Day
- 48th Annual Meeting of the EBMT: CTIWP session
- CTIWP Scientific Business Meeting - June 15, 2022
- CTIWP Scientific Business Meeting - Sep. 30, 2022
- Joint Meeting of the ALWP and CTIWP (Virtual) - Sep. 30 - Oct. 1, 2022

**VISIT THE CTIWP WEBPAGE**